newsfilter
← Latest News
PR Newswire·

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

CAI
  • Caris Life Sciences launched the "Behind the Diagnosis" campaign to highlight patients whose care was personalized through comprehensive molecular profiling & AI.
  • The inaugural story features Erika Rios, whose presumed stage 4 metastatic triple-negative breast cancer diagnosis was corrected to treatable Hodgkin lymphoma by Caris GPSai.
  • Oncologist Vitor H. Pastorini Filho ordered Caris GPSai testing after noting the initial diagnosis did not match the clinical picture.
  • Caris GPSai is a clinically validated tissue-of-origin AI model available at no additional cost when ordering Caris MI Cancer Seek.
  • Caris MI Cancer Seek received FDA approval in November 2024 as the first & only simultaneous Whole Exome Sequencing & Whole Transcriptome Sequencing assay with FDA-approved companion diagnostic indications.
  • A peer-reviewed study in JAMA Network Open showed GPSai identified 123 misdiagnoses among 3,958 cases of presumed lung squamous cell carcinoma, a 3.1% error rate.
  • Following diagnosis corrections in the JAMA study, 71.5% of patients became eligible for guideline-preferred first-line systemic therapies.
  • Matthew Oberley, MD, PhD, stated that integrating tissue-of-origin prediction provides clinicians a powerful second look without requiring additional specimens or delays.
  • Erika Rios was successfully treated for her corrected Hodgkin lymphoma diagnosis & shared her relief at the life-saving intervention.
  • The "Behind the Diagnosis" campaign will feature additional patient stories illustrating real-world outcomes from genomic profiling & AI throughout the coming year.